Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 20 | 2023 | 43 | 3.620 |
Why?
|
| Anaphylaxis | 3 | 2023 | 10 | 1.320 |
Why?
|
| Asthma | 7 | 2023 | 156 | 0.750 |
Why?
|
| Epinephrine | 3 | 2023 | 32 | 0.700 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2008 | 9 | 0.590 |
Why?
|
| Sinusitis | 5 | 2018 | 162 | 0.580 |
Why?
|
| Child | 13 | 2023 | 1295 | 0.580 |
Why?
|
| Child Day Care Centers | 2 | 2006 | 5 | 0.510 |
Why?
|
| Surveys and Questionnaires | 7 | 2023 | 1144 | 0.500 |
Why?
|
| Caregivers | 3 | 2023 | 197 | 0.490 |
Why?
|
| Rhinitis, Allergic | 3 | 2023 | 16 | 0.480 |
Why?
|
| Rhinitis | 4 | 2018 | 144 | 0.470 |
Why?
|
| Dermatitis, Atopic | 3 | 2018 | 14 | 0.370 |
Why?
|
| Mast Cells | 2 | 2008 | 17 | 0.370 |
Why?
|
| Allergens | 4 | 2023 | 16 | 0.360 |
Why?
|
| Humans | 33 | 2023 | 27072 | 0.360 |
Why?
|
| Gastroesophageal Reflux | 2 | 2021 | 27 | 0.320 |
Why?
|
| Adolescent | 7 | 2023 | 2172 | 0.300 |
Why?
|
| Immunity, Innate | 1 | 2008 | 57 | 0.290 |
Why?
|
| Hypersensitivity | 1 | 2008 | 47 | 0.280 |
Why?
|
| Child, Preschool | 7 | 2021 | 641 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 164 | 0.280 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2018 | 158 | 0.250 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2004 | 7 | 0.230 |
Why?
|
| Peroxidase | 1 | 2004 | 14 | 0.230 |
Why?
|
| Infant | 6 | 2021 | 564 | 0.230 |
Why?
|
| Vasculitis | 1 | 2004 | 26 | 0.230 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2014 | 53 | 0.230 |
Why?
|
| Infant, Premature, Diseases | 1 | 2004 | 30 | 0.230 |
Why?
|
| Lung Diseases | 1 | 2004 | 45 | 0.220 |
Why?
|
| Hemorrhage | 1 | 2004 | 81 | 0.220 |
Why?
|
| Kidney Diseases | 1 | 2004 | 72 | 0.220 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2023 | 3 | 0.210 |
Why?
|
| Female | 18 | 2022 | 15212 | 0.200 |
Why?
|
| Shellfish Hypersensitivity | 1 | 2022 | 1 | 0.200 |
Why?
|
| Cockroaches | 1 | 2022 | 2 | 0.200 |
Why?
|
| Celiac Disease | 1 | 2002 | 7 | 0.200 |
Why?
|
| Digestive System | 1 | 2002 | 14 | 0.200 |
Why?
|
| Pancreatitis | 1 | 2002 | 21 | 0.190 |
Why?
|
| Crohn Disease | 1 | 2002 | 40 | 0.190 |
Why?
|
| Male | 17 | 2022 | 14772 | 0.190 |
Why?
|
| Quality of Life | 2 | 2023 | 629 | 0.180 |
Why?
|
| Prospective Studies | 5 | 2023 | 1778 | 0.180 |
Why?
|
| Diet | 2 | 2021 | 220 | 0.180 |
Why?
|
| Bullying | 1 | 2020 | 4 | 0.180 |
Why?
|
| Microbiota | 2 | 2018 | 95 | 0.170 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2013 | 6 | 0.170 |
Why?
|
| Chronic Disease | 6 | 2018 | 415 | 0.170 |
Why?
|
| Mastocytosis | 1 | 2019 | 1 | 0.160 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 156 | 0.160 |
Why?
|
| Poverty | 1 | 2020 | 96 | 0.160 |
Why?
|
| Parents | 1 | 2020 | 113 | 0.160 |
Why?
|
| Physicians | 1 | 2020 | 122 | 0.150 |
Why?
|
| Rhinitis, Allergic, Seasonal | 2 | 2008 | 6 | 0.150 |
Why?
|
| Adult | 10 | 2018 | 7831 | 0.150 |
Why?
|
| Prevalence | 4 | 2023 | 443 | 0.140 |
Why?
|
| Nose | 1 | 2018 | 38 | 0.140 |
Why?
|
| Dietary Fiber | 1 | 2017 | 27 | 0.140 |
Why?
|
| Pollen | 1 | 2016 | 2 | 0.140 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2016 | 3 | 0.130 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 64 | 0.130 |
Why?
|
| Minority Groups | 1 | 2016 | 80 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 77 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 88 | 0.120 |
Why?
|
| Nasal Polyps | 1 | 2016 | 54 | 0.120 |
Why?
|
| Middle Aged | 9 | 2018 | 8923 | 0.120 |
Why?
|
| Granulocytes | 1 | 2014 | 15 | 0.120 |
Why?
|
| Toll-Like Receptors | 1 | 2014 | 17 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2014 | 77 | 0.110 |
Why?
|
| United States | 4 | 2021 | 2035 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 10 | 0.110 |
Why?
|
| Hospitalization | 1 | 2016 | 300 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 56 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2016 | 642 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2016 | 270 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2022 | 1890 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 245 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 198 | 0.090 |
Why?
|
| Receptors, IgE | 1 | 2009 | 1 | 0.080 |
Why?
|
| Immunoglobulin E | 1 | 2009 | 11 | 0.080 |
Why?
|
| Pregnancy | 2 | 2013 | 336 | 0.080 |
Why?
|
| Neutrophils | 1 | 2009 | 104 | 0.080 |
Why?
|
| South Africa | 2 | 2018 | 13 | 0.070 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2008 | 5 | 0.070 |
Why?
|
| Aged | 5 | 2016 | 8997 | 0.070 |
Why?
|
| Risk Factors | 2 | 2017 | 2302 | 0.070 |
Why?
|
| Cytokines | 1 | 2008 | 222 | 0.070 |
Why?
|
| Health Education | 1 | 2006 | 48 | 0.070 |
Why?
|
| Data Collection | 1 | 2006 | 91 | 0.070 |
Why?
|
| Enterocolitis | 1 | 2006 | 4 | 0.060 |
Why?
|
| Mastocytosis, Systemic | 1 | 2006 | 7 | 0.060 |
Why?
|
| Diarrhea | 1 | 2006 | 34 | 0.060 |
Why?
|
| Illinois | 2 | 2017 | 250 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2005 | 8 | 0.060 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 17 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2004 | 67 | 0.060 |
Why?
|
| Depression | 1 | 2008 | 444 | 0.050 |
Why?
|
| Young Adult | 3 | 2018 | 1994 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 115 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2004 | 218 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2016 | 3538 | 0.050 |
Why?
|
| Dermatophagoides pteronyssinus | 1 | 2022 | 1 | 0.050 |
Why?
|
| Dust | 1 | 2022 | 2 | 0.050 |
Why?
|
| Pyroglyphidae | 1 | 2022 | 2 | 0.050 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2022 | 2 | 0.050 |
Why?
|
| Gastric Acid | 1 | 2002 | 9 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2022 | 53 | 0.050 |
Why?
|
| Permeability | 1 | 2002 | 97 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2002 | 143 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2002 | 24 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 879 | 0.050 |
Why?
|
| Acute Disease | 1 | 2002 | 176 | 0.050 |
Why?
|
| Shellfish | 1 | 2021 | 2 | 0.050 |
Why?
|
| Schools | 1 | 2020 | 43 | 0.040 |
Why?
|
| Food | 1 | 2020 | 34 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 395 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 102 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 891 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 4777 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 71 | 0.040 |
Why?
|
| Biodiversity | 1 | 2018 | 35 | 0.040 |
Why?
|
| Syndrome | 1 | 2016 | 76 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 420 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 68 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 115 | 0.030 |
Why?
|
| Aspirin | 1 | 2016 | 83 | 0.030 |
Why?
|
| Exhalation | 1 | 2014 | 3 | 0.030 |
Why?
|
| Spirometry | 1 | 2014 | 10 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 312 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 61 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 29 | 0.030 |
Why?
|
| Animals | 1 | 2022 | 3642 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2014 | 79 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2013 | 12 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 256 | 0.030 |
Why?
|
| Vincristine | 1 | 2013 | 23 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2013 | 14 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 48 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 30 | 0.030 |
Why?
|
| Rituximab | 1 | 2013 | 48 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2013 | 50 | 0.030 |
Why?
|
| Prednisone | 1 | 2013 | 66 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2013 | 57 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2014 | 587 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 271 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2014 | 458 | 0.020 |
Why?
|
| Basophils | 1 | 2009 | 7 | 0.020 |
Why?
|
| Superoxides | 1 | 2009 | 25 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 147 | 0.020 |
Why?
|
| Ranitidine | 1 | 2006 | 3 | 0.020 |
Why?
|
| Cetirizine | 1 | 2006 | 3 | 0.020 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2006 | 3 | 0.020 |
Why?
|
| Tryptases | 1 | 2006 | 5 | 0.020 |
Why?
|
| Duodenum | 1 | 2006 | 5 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2006 | 15 | 0.020 |
Why?
|
| Cell Count | 1 | 2006 | 81 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 161 | 0.020 |
Why?
|
| Colon | 1 | 2006 | 119 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 3485 | 0.010 |
Why?
|